Itraconazole Capsule 200 mg use Vulvovaginal candidiasis, Oropharyngeal candidosis, Pityriasis versicolor,Systemic candidiasis, Histoplasmosis,
Dermatophytoses caused by organisms susceptible to itraconazole (Trichophyton spp., Microsporum spp.,Epidermophyton floccosum) e.g. tinea pedis, tinea cruris, tinea corporis, tinea manuum,
Onychomycoses caused by dermatophytes and/or yeasts,
Cryptococcal infections (including cryptococcal meningitis). In immunosuppressed patients suffering fromcryptococcosis and in patients with cryptococcosis of the CNS Itraconazole is indicated only if the usually recommendedinitial therapy seems to be inappropriate or ineffective.
Aspergillosis. Itraconazole can be used to treat patients suffering from invasive aspergillosis who were found to berefractory or intolerant to Amphotericin B.
Maintenance therapy in AIDS patients to prevent relapse of underlying fungal infection who were found to be refractoryor intolerant to first-line systemic anti-fungal therapy is inappropriate or has proved ineffective.
Itraconazole Capsule 200 mg is for oral administration and must be taken immediately after a meal for maximal absorption. The capsulesmust be swallowed whole.
Abdominal Pain, Nausea, Uncommon:Vomiting, Diarrhoea, Constipation, Dyspepsia, Dysgeusia, Flatulence, Rash,.
There is no information regarding cross hypersensitivity between itraconazole and other azole antifungal agents. Cautionshould be used in prescribing Itraconazole Capsule 200 mg Capsules to patients with hypersensitivity to other azoles.
Itraconazole has been shown to have a negative inotropic effect and has been associated withreports of congestive heart failure. Itraconazole should not be used in patients with congestive heart failure or with a history of congestive heart failure unlessthe benefit clearly outweighs the risk.
Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should beexercised when the drug is administered in this patient population. It is recommended that patients with impaired hepaticfunction be carefully monitored when taking itraconazole.
Clinical data on the use of itraconazole in paediatric and elderly patients is limited.The use of Itraconazole inpaediatric and elderly patients is not recommended unless it is determined that the potential benefit outweighs the potential risks.
Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several ofthese reports included concurrent administration of quinidine which is contraindicated. The hearing loss usually resolves when treatment is stopped,but can persist in some patients.
Due to the pharmacokinetic properties, itraconazole capsules are notrecommended for initiation of treatment in patients with immediately life-threatening systemic fungal infections.
In systemic candidosis, if fluconazole-resistant strains of Candida species are suspected, it cannot be assumed thatthese are sensitive to itraconazole, hence their sensitivity should be tested before the start of Itraconex-200 therapy.
If neuropathy occurs which may be attributable to itraconazole Capsules, the treatment should be discontinued.
In patients with AIDS having received treatment for a systemic fungal infection such as sporotrichosis, blastomycosis,histoplasmosis or cryptococcosis (meningeal or non-meningeal) and who are considered at risk for relapse, the treatingphysician should evaluate the need for a maintenance treatment.
Store below 30°C, protect from light and moisture
Keep the medicine out of reach of children.
10 x 10 Alu/PVC blister pack
Itraconex-200 is available in an Alu/PVC blister of 10 capsules. Such 10 blisters in a unit carton with package insert.